Eli Lilly and Company $LLY Shares Acquired by Howe & Rusling Inc.

Howe & Rusling Inc. increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 110.1% in the 2nd quarter, HoldingsChannel reports. The firm owned 895 shares of the company’s stock after buying an additional 469 shares during the quarter. Howe & Rusling Inc.’s holdings in Eli Lilly and Company were worth $698,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. PNC Financial Services Group Inc. lifted its position in shares of Eli Lilly and Company by 97.5% in the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock valued at $83,669,349,000 after acquiring an additional 50,002,551 shares in the last quarter. Vanguard Group Inc. increased its position in Eli Lilly and Company by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock worth $62,680,004,000 after purchasing an additional 1,183,038 shares in the last quarter. Wellington Management Group LLP raised its stake in Eli Lilly and Company by 0.6% in the 1st quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company’s stock valued at $10,495,261,000 after purchasing an additional 81,587 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Eli Lilly and Company by 13.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company’s stock valued at $4,808,443,000 after purchasing an additional 682,203 shares in the last quarter. Finally, Nuveen LLC acquired a new stake in shares of Eli Lilly and Company during the 1st quarter worth about $4,613,912,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the stock. Leerink Partnrs raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 10th. Truist Financial raised their target price on shares of Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the stock a “buy” rating in a research report on Wednesday. Wall Street Zen upgraded Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 1st. Daiwa Capital Markets increased their price target on Eli Lilly and Company from $700.00 to $940.00 in a research note on Monday, November 10th. Finally, Guggenheim restated a “buy” rating and set a $948.00 price objective on shares of Eli Lilly and Company in a report on Thursday, October 16th. Three analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $1,027.95.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,042.86 on Friday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The company has a market cap of $985.90 billion, a P/E ratio of 68.16, a P/E/G ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,057.00. The firm’s 50 day moving average is $849.83 and its two-hundred day moving average is $786.02.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business’s quarterly revenue was up 53.9% compared to the same quarter last year. During the same period in the previous year, the company earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be paid a dividend of $1.50 per share. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.